The significant elevations in CD4+, CD8+ and Treg populations in peripheral blood following NanoDoce treatments suggests that circulating immune effector cells contributed to the growth inhibition of the primary tumors treated with NanoDoce and may have had an effect on the secondary untreated tumor. The gene discussed is CD8A; the disease is neoplasm.